📅 PUBMED DAILY TRIAGE — 2026-05-13

Window: 2026-05-12T09:00Z → 2026-05-13T09:00Z (CRDT) Topics scanned: 9 | Articles reviewed: 88 unique PMIDs | Candidates evaluated: ~87 High priority: 6 | Standard: 19 | Low/archive: 62 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

TR-001 / PMID 42120728 · CRISPR-Cas9 CD33-deleted allogeneic HCT with gemtuzumab ozogamicin maintenance in AML (Phase 1/2) · 9/10 · First-in-class CRISPR antigen-deletion strategy allows post-HCT GO maintenance without destroying donor graft; all 30 patients engrafted by day 28; trial stopped early but proof-of-concept established. (Nat Med)

Novel Therapeutics / Immunotherapy

TR-004 / PMID 42120910 · Adjuvant personalized neoantigen DNA vaccination for MGMT-unmethylated glioblastoma: Phase 1 · 8/10 · Personalized DNA vaccine with up to 40 neoantigens/patient met pre-specified 6-mo PFS and 12-mo OS endpoints in 9 GBM patients; no serious AEs; one 4-year long-term survivor. (Nat Cancer)

Cardiovascular-Metabolic / GLP-1

TR-002 / PMID 42120723 · Orforglipron Phase 3b ATTAIN-MAINTAIN trial — oral GLP-1RA maintains weight loss after injectable therapy · 9/10 · Once-daily oral orforglipron maintained 74.7–79.3% of body weight reduction achieved on tirzepatide/semaglutide vs 37.6–49.2% placebo in 376 patients (P<0.001 both cohorts); all secondary endpoints met. (Nat Med)

TR-005 / PMID 42120725 · Pasteurized Akkermansia muciniphila MucT for weight loss maintenance: RCT · 8/10 · First RCT evidence of A. muciniphila MucT significantly reducing post-diet weight regain (1.2 vs 3.2 kg placebo, P=0.012) in 90 participants; no serious AEs. (Nat Med)

Early Cancer Detection

TR-006 / PMID 42116274 · SPECTRAL photonic hydrogel platform for ctDNA multi-cancer detection · 7/10 + 🔴EARLY_CANCER_DETECTION · Sequencing-free plasma platform profiles 205 ctDNA mutations + 8 proteins simultaneously; 87.5% accuracy for lung/breast/colorectal classification within 100 min. (Angew Chem Int Ed)

Rare Diseases

TR-003 / PMID 42116163 · Unprocessed U1 snRNAs as biomarker of INTS11- and BRAT1-related neurodevelopmental disorders · 9/10 · First disclosure of BRAT1's role in RNA processing; U1 snRNA misprocessing severity directly predicts clinical severity in BRAT1/INTS11 NDDs; zebrafish model validates causal link. (Genome Med)

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• TR-007 / PMID 42120929 · NUP98r AML comprehensive cohort (n=95) — FLT3i improves 5-yr OS to 53.3% · 7/10 · Genomics/Precision Medicine (Leukemia)
• TR-008 / PMID 42120657 · Czech CLL: BTKi vs VenR real-world second-line comparison (n=352) — comparable PFS/OS, more BTKi discontinuations · 6/10 · Treatment Innovation (Ann Hematol)
• TR-009 / PMID 42118701 · Single-cell mechanodeformation signatures as hematologic malignancy biomarkers (review) · 5/10 · Diagnostics (Crit Rev Clin Lab Sci)

CBC/ML Hematology (22nd consecutive sparse window)

No ≥5 articles classified. Best candidate: PMID 42119559 (Dev Cell ML megakaryocyte identification system) — abstract truncated during retrieval; deferred to next run. PMID 42120994 (rank 1 in topic list) also not retrieved; deferred.

Early Cancer Detection

• TR-010 / PMID 42119346 · Immunopeptidomics + liquid biopsy integration for precision oncology (review) · 5/10 · Early Detection (Mol Aspects Med)
• TR-011 / PMID 42119195 · ctDNA detection in pseudomyxoma peritonei: limited utility (n=95, 8% detection rate) · 5/10 · Diagnostics (Eur J Surg Oncol)

AI/ML in Clinical Diagnostics

• TR-012 / PMID 42120190 · Peripheral UWF imaging biomarkers predict DR progression 2yr prospective (n=528) — OR 3.09–4.00 · 7/10 · Diagnostics (Br J Ophthalmol)
• TR-013 / PMID 42120650 · SHAP-interpretable ML for stroke risk using serum miRNA (n=1785 training) · 6/10 · Diagnostics (J Mol Neurosci)
• TR-014 / PMID 42120887 · IC-ECIS single-cell impedance chip: intraoperative tumor diagnosis in 20 min at $1/chip · 6/10 · Diagnostics (Microsyst Nanoeng)
• TR-015 / PMID 42120702 · SERS + XGBoost for CKD early diagnosis using serum KIM-1 (98.4% accuracy) · 6/10 · Diagnostics (Mikrochim Acta)
• TR-016 / PMID 42118628 · MILA-MIL: Mamba-inspired WSI survival prediction across 6 cancer cohorts · 6/10 · Precision Oncology (IEEE J Biomed Health Inform)

Precision Oncology

• TR-017 / PMID 42120924 · NSCLC blood proteomics (SomaScan + NULISA, n=56) — distinct signatures for surgical recurrence and ICI response · 7/10 · Diagnostics (NPJ Precis Oncol)
• TR-018 / PMID 42118848 · CM-LP11 lactylation-methylation prognostic model for cutaneous melanoma (TCGA + 2 validation cohorts) · 5/10 · Genomics/Precision Medicine (Epigenetics)

Immunotherapy / Novel Therapeutics

• TR-019 / PMID 42120266 · Feladilimab + docetaxel Phase 2 NSCLC: negative OS (7.8 vs 8.2 mo, HR 1.5) — ICOS agonism insufficient · 5/10 · Treatment Innovation (Clin Lung Cancer)
• TR-020 / PMID 42120578 · FMISO PET early changes as ICI response predictor in NSCLC pilot (n=17) · 5/10 · Diagnostics (Sci Rep)
• TR-021 / PMID 42120181 · Alloantigen-expressing oncolytic virotherapy converts immune-cold PDAC; synergy with checkpoint blockade in mice · 5/10 · Treatment Innovation (J Immunother Cancer)

Cardiovascular-Metabolic

• TR-022 / PMID 42120922 · Obesity medication costs comparison (n=228K): liraglutide +73.6% costs vs phentermine without utilization benefit · 6/10 · Public Health (Obesity)
• TR-023 / PMID 42120704 · Prepregnancy GLP-1RA associated with higher preeclampsia risk (n=31, signal only) · 5/10 · Drug Development (Obesity)

Aging / Longevity

• TR-024 / PMID 42120013 · Caring in later life and cognitive trajectories: ELSA n=2765 — intensity matters, high-intensity care accelerates decline · 6/10 · Public Health (Age Ageing)
• TR-025 / PMID 42118429 · Gut microbiota aging review — conserved SCFA, bile acid, tryptophan signatures · 5/10 · Diagnostics (World J Microbiol Biotechnol)

Rare Diseases

• PMID 42118762: EGPA plasma metabolomics (n=10 per group) — AUC >0.8 for 21/24 candidate metabolites · 5/10 · Diagnostics (PLoS One) — count included in triage JSON below standard limit; n=10 too small for JSON record
• PMID 42119630: Polycystic bone disease new family report · 4/10 · LOW (Bone)

💡 UNSOLICITED FINDS

None identified in this window. All high-signal finds from the sentinel scan (848 results) were already captured by watchlist topic searches. The Nat Med cluster (TR-001, TR-002, TR-005) and Nat Cancer GBM vaccine (TR-004) were the most notable discoveries.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 6 (TR-001, TR-004, TR-005, TR-008, TR-019, TR-021)
• Diagnostics: 10 (TR-003, TR-009, TR-010, TR-011, TR-012, TR-013, TR-014, TR-015, TR-017, TR-020)
• Drug Development: 4 (TR-002, TR-022, TR-023, genomics overlap)
• Genomics/Precision Medicine: 3 (TR-003, TR-016, TR-018)
• Public Health: 3 (TR-022, TR-024, TR-025)
• Early Detection: 2 (TR-006, TR-010)

By evidence maturity:

• Exploratory: 14
• Validated: 9
• Potentially Practice-Changing: 0

By watchlist topic — reviewed / kept (HIGH+STANDARD) / highest score:

By source type: peer_reviewed 25 | preprint 0

Topics with zero 8+ articles this run (HIGH by score ≥8 only):

• CBC/ML hematology (22nd consecutive)
• AI/ML diagnostics
• Precision oncology
• Aging/longevity

🔧 RUN NOTES

Window: Standard 24h CRDT window (2026-05-12T09:00Z → 2026-05-13T09:00Z). No expansion triggered (≥5 relevant records found).

Notable cluster: Three simultaneous Nature Medicine publications (PMID 42120723 orforglipron, 42120725 Akkermansia RCT, 42120728 CRISPR AML HCT) on the same CRDT date. Likely timed to a major conference or editorial cluster. All three are HIGH priority.

CBC/ML hematology (22nd consecutive sparse window): Two potentially relevant articles deferred:

• PMID 42119559 (Dev Cell): "A machine learning-based megakaryocyte identification system uncovers resident organs, markers, and functional diversity" — abstract retrieval truncated; high relevance to this topic. Recommend prioritized review next run.
• PMID 42120994 (top-ranked in CBC/ML query and 2nd in AI/ML query): abstract not retrieved due to response truncation. Deferred to next run.

Truncation: AI/ML diagnostics (150 raw results), immunotherapy (90), cardiometabolic (82), and sentinel scan (848) all had significant tail not reviewed. Top 10 per topic retrieved per schema. Sentinel scan top 8/10 retrieved; all high-signal sentinel results already captured by watchlist topics.

Trem-cel trial caveats: PMID 42120728 scored 9 (NOVEL_TREATMENT, HIGH) but trial was stopped early; 3/30 TRM noted. Phase 2 expansion enrolled only 4 patients. Clinical readiness remains in Phase 1 territory.

Rolling 7-day state (from state.json): CBC/ML hematology has been sparse for 22 consecutive runs. GLP-1/SGLT2 cardiometabolic remains the highest-scoring topic (highest score 9/10 in 3 of last 5 runs). Rare diseases topic produced first HIGH score this week.